TITLE

FDA CLEARS FIRST RADIOLOGY APP FOR MOBILE DEVICES

AUTHOR(S)
ROBERTS, MARY ROSE
PUB. DATE
March 2011
SOURCE
Urgent Communications;Mar2011, Vol. 29 Issue 3, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that the U.S. Food and Drug Administration (FDA) has cleared a mobile radiology application that lets doctors view medical images sent via an application called Mobile MIM Suite on a portable wireless device like Apple iPhone.
ACCESSION #
59414380

 

Related Articles

  • FDA Consumer Update.  // Medical Imaging;Aug2008, Vol. 23 Issue 8, p12 

    The article deals with the report "Radiology and Children: Extra Care Required," issued by the U.S. Food and Drug Administration (FDA) in August 2008. Particular focus is given on the significance of optimizing computed tomography settings for pediatric patients. Identified in the report are the...

  • FDA Takes a Stand On CT Scans for People Without Symptoms. Napoli, Maryann // HealthFacts;Jun2002, Vol. 27 Issue 6, p6 

    Focuses on a statement issued by the U.S. Food and Drug Administration (FDA) regarding the use of computerized tomography (CT) scans to people without symptoms. Intended function of CT scans according to FDA; Views of the American College of Radiology on CT scans for people without symptoms;...

  • Digital Breast Tomosynthesis. Bladwin, Pat // Radiologic Technology;Sep/Oct2009, Vol. 81 Issue 1, p57M 

    Digital breast tomosynthesis (DBT) is a new technology that combines the use of tomography and 3-D reconstruction with breast imaging to improve lesion visibility. Although no DBT equipment yet has been approved by the U.S. Food and Drug Administration, the technology is creating interest in the...

  • A return to basics, a focus on the future.  // Journal of Nuclear Cardiology;Dec2011, Vol. 18 Issue 6, p1116 

    No abstract available.

  • On and Offsite Image Reads. Patt, Rick; Shamsi, Kohkan // Applied Clinical Trials;Jan2010 Supplement, p6 

    In this article, the authors discuss the use of medical imaging drug in clinical trials as a measure of efficacy for managing individual patients in the U.S. They indicate that the diagnostic-derived blinded read process used across therapeutic sites is derived from the U.S. Food & Drug...

  • FDAer asserts clinical testing essential.  // Medical Device Daily;11/19/2009, Vol. 13 Issue 224, p7 

    The article highlights the assertion of Dr. Robert Smith of the Center for Devices and Radiological Health (CDRH) during a panel discussion about the need for quantity and quality on the clinical performance of the U.S. Food and Drug Administration (FDA) to uphold equivalence in both screening...

  • A Step Closer. DIIULIO, RENEE // Medical Imaging;Oct2008, Vol. 23 Issue 10, p50 

    The article discusses the need for more specific contrast agents, whether organ-specific, disease-specific, or mechanism-specific, for radiology and diagnostic imaging system. Information is given on some new contracts agents approved by the U.S. Food and Drug Administration. It also examines a...

  • Ultra-low-dose imaging system may offer up to 89% less radiation exposure vs. computed radiography.  // Infectious Diseases in Children;May2010, Vol. 23 Issue 5, p46 

    The article reports that Rady Children's Hospital-San Diego in California has become the first pediatric specialty center in the U.S. to have an EOS ultra-low-dose imaging system for the pediatric spine approved by the Food and Drug Administration (FDA).

  • MITA: FDA resumes contrast agent reviews. McCARTY, MARK // Medical Device Daily;12/27/2010, Vol. 14 Issue 249, p5 

    The article deals with a statement issued by the Medical Imaging & Technology Alliance (MITA) on December 22, 2010 that the U.S. Food and Drug Administration (FDA) resumed processing reviews of contrast agent applications submitted in early 2010.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics